Latest Earnings Results: Q3 '26
Estimated EPS
$0.07
Reported EPS
$0.28
Surprise
+284.31%
Estimated Rev
$122.93M
Reported Rev
$123.1M
Surprise
+0.14%
• Reported GAAP EPS of $0.28 down -47.17% YoY • Reported revenue of $123.1M up 5.45% YoY • GeneDx reiterated full year 2026 revenue guidance of $475 to $490M and expects fourth quarter revenue of $135M, adjusted gross margin of at least 71%, and adjusted net income of approximately $12M.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.39 | -- | -- | N/A |
Q3 '26 | $0.07 | $0.28 | 284.31% | BEAT |
Q2 '26 | -$0.19 | $0.01 | 105.32% | BEAT |
Q1 '26 | -$0.01 | -$0.28 | -1766.67% | MISSED |
Q4 '25 | $0.12 | $0.14 | 16.85% | BEAT |